BBM-P002 Gene Therapy Shows Promise in Treating Parkinson’s Disease with 12-Month Motor Improvements

A Phase 1 multicenter trial of the gene therapy BBM-P002 demonstrated that the treatment is safe and well-tolerated in patients with Parkinson’s disease, according to a study published June 10, 2026, in Nature Medicine. The therapy showed motor improvements over 12 months by co-delivering two enzymes, tyrosine hydroxylase (TH) and aromatic L-amino acid decarboxylase (DDC), to restore dopamine production in the brain.

Researchers reported that the dual-target approach was well-tolerated by participants throughout the study period. The trial focused on the safety and initial therapeutic potential of the gene therapy, which targets the metabolic pathway responsible for synthesizing dopamine.

The Nature Medicine report indicates that participants experienced motor improvements that persisted through the 12-month mark. These results suggest the therapy can successfully modify the cellular environment to support dopamine production.

How does BBM-P002 restore dopamine?

BBM-P002 uses a viral vector to deliver the genetic instructions for two specific enzymes, TH and DDC, directly into the brain. These enzymes work in sequence to convert the amino acid tyrosine into dopamine, the neurotransmitter that degrades in Parkinson’s disease.

In a healthy brain, these enzymes operate in dopamine-producing neurons. In Parkinson’s patients, the loss of these neurons leads to motor dysfunction. BBM-P002 aims to turn non-dopaminergic cells into producers of dopamine to compensate for the loss.

Why is a dual-target therapy used?

The dual-target design addresses a limitation found in earlier single-gene therapy attempts. Many previous research efforts focused only on delivering TH, the rate-limiting enzyme in dopamine synthesis.

According to the study, co-delivering both TH and DDC creates a more efficient metabolic pipeline. While TH creates L-DOPA, DDC is required to convert that L-DOPA into active dopamine. Providing both enzymes reduces the reliance on the brain’s remaining endogenous DDC, which is often depleted in advanced Parkinson’s disease.

This differs from standard pharmacological treatments like Levodopa. Levodopa provides the raw material for dopamine, but it requires the brain to have functioning DDC enzymes to work. BBM-P002 provides both the machinery and the instructions to produce the neurotransmitter internally.

What were the primary outcomes of the Phase 1 trial?

The primary goal of the multicenter trial was to establish the safety profile of the therapy. The researchers found no dose-limiting toxicities or severe adverse reactions linked to the delivery of the TH and DDC genes.

Beyond safety, the trial tracked motor function over a full year. The data showed a signal of therapeutic potential, with participants exhibiting improved motor control compared to their baseline measurements.

What happens next for BBM-P002?

Because the Phase 1 trial confirmed that BBM-P002 is safe and well-tolerated, the research can move toward larger Phase 2 trials. These future studies will likely focus on determining the optimal dosage and measuring the efficacy of the treatment across a broader, more diverse patient population.

The researchers noted that the 12-month motor improvements provide a foundation for further testing. They aim to determine if the therapy can reduce the need for daily dopaminergic medications or stabilize the progression of motor symptoms over longer periods.